ADAM11 (NM_002390) Human Tagged ORF Clone

CAT#: RC220941L3

  • LentiORF®

Lenti ORF clone of Human ADAM metallopeptidase domain 11 (ADAM11), Myc-DDK-tagged


  "NM_002390" in other vectors (4)

Reconstitution Protocol

USD 1,060.00

3 Weeks*

Size
    • 10 ug

Product Images

Other products for "ADAM11"

Specifications

Product Data
Type Human Tagged ORF Clone
Tag Myc-DDK
Symbol ADAM11
Synonyms MDC
Vector pLenti-C-Myc-DDK-P2A-Puro
E. coli Selection Chloramphenicol (34 ug/mL)
Mammalian Cell Selection Puromycin
Sequence Data
The ORF insert of this clone is exactly the same as(RC220941).
Restriction Sites SgfI-MluI      Cloning Scheme for this gene     
ACCN NM_002390
ORF Size 2307 bp
OTI Disclaimer The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info
OTI Annotation This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene.
Reference Data
RefSeq NM_002390.4, NP_002381.2
RefSeq Size 4402
RefSeq ORF 2310
Locus ID 4185
Protein Families Druggable Genome, Transmembrane
MW 83.2 kDa
Gene Summary This gene encodes a member of the ADAM (a disintegrin and metalloprotease) protein family. Members of this family are membrane-anchored proteins structurally related to snake venom disintegrins, and have been implicated in a variety of biological processes involving cell-cell and cell-matrix interactions, including fertilization, muscle development, and neurogenesis. The encoded preproprotein is proteolytically processed to generate the mature protease. This gene represents a candidate tumor suppressor gene for human breast cancer based on its location within a minimal region of chromosome 17q21 previously defined by tumor deletion mapping. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Jan 2016]

Other Versions

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.